Review article| Volume 75, ISSUE 5, P328-336, May 2007

Range of published estimates of venous thromboembolism incidence in young women



      This review was conducted to show the full range of incidence estimates published for venous thromboembolism (VTE) in women depending on study design and to suggest a more reliable estimate for women of reproductive age.


      A literature search was performed to identify studies on the incidence of VTE in women. Incidence rates were compiled from studies with different methodologies and varying methodological quality. Algorithms were used to estimate VTE incidence from more reliable studies in young women.

      Results and Discussion

      The literature shows two levels of VTE incidence rates: community/cohort studies and database studies. The estimated VTE incidence for women of reproductive age was 5.5���13.5 and 3.8���12.2 in community and cohort studies, respectively, but only 0.7���3.8 per 10,000 women-years (WY) in database studies. This difference is probably attributable to methodological problems associated with some database studies.


      The VTE incidence in women of reproductive age is likely to be in the range of 5���10 per 10,000 WY. These rates for the background incidence are clearly higher than the reference figures that are often utilized in the comparison with users of hormonal contraception (0.5���1 VTE per 10,000 WY).


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease.
        Lancet. 1995; 346: 1582-1588
        • Spitzer W.O.
        • Lewis M.A.
        • Heinemann L.A.
        • Thorogood M.
        • MacRae K.D.
        Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
        BMJ. 1996; 312: 83-88
        • Heinemann L.A.J.
        • Lewis M.A.
        • Assmann A.
        • Thiel C.
        Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use.
        Contraception. 2002; 65: 207-214
        • Scurr J.H.
        • Machin S.J.
        • Bailey-King S.
        • Mackie I.J.
        • McDonald S.
        • Smith P.D.
        Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial.
        Lancet. 2001; 357: 1485-1489
        • Belcaro G.
        • Geroulakos G.
        • Nicolaides A.N.
        • Myers K.A.
        • Winford M.
        Venous thromboembolism from air travel: the LONFLIT study.
        Angiology. 2001; 52: 369-374
        • Schwarz T.
        • Siegert G.
        • Oettler W.
        • et al.
        Venous thrombosis following long-haul flights.
        Arch Intern Med. 2003; 163: 2759-2764
        • European Agency for the Evaluation of Medicinal Products
        Combined oral contraceptives and venous thromboembolism. The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products (CPMP); public assessment report. London, 28 September 2001.
        ([online] Available from) ([Accessed Oct. 30, 2006])
        • Fowkes F.J.
        • Price J.F.
        • Fowkes F.G.
        Incidence of diagnosed deep vein thrombosis in the general population: systematic review.
        Eur J Vasc Endovasc Surg. 2003; 25: 1-5
        • Anderson Jr, F.A.
        • Wheeler H.B.
        • Goldberg R.J.
        • et al.
        A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study.
        Arch Intern Med. 1991; 151: 933-938
        • Kniffin W.D.
        • Baron J.A.
        • Barrett J.
        • Birkmeyer J.D.
        • Anderson F.A.
        The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly.
        Arch Int Med. 1994; 154: 861-866
        • Nordstr��m M.
        • Lindblad B.
        • Bergqvist D.
        • Kjellstrom T.
        A prospective study of the incidence of deep-vein thrombosis within a defined urban population.
        J Intern Med. 1992; 232: 155-160
        • Silverstein M.D.
        • Heit J.A.
        • Mohr D.N.
        • Petterson T.M.
        • O'Fallon W.M.
        • Melton III, L.J.
        Trends in the incidence of deep venous thrombosis and pulmonary embolism: a 25-year population-based study.
        Arch Intern Med. 1998; 158: 585-593
        • Nylander G.
        • Olivecrona H.
        The phlebographic pattern of acute leg thrombosis within a defined urban population.
        Acta Chir Scand. 1976; 142: 505-511
        • Kierkegaard A.
        Incidence of acute deep vein thrombosis in two districts.
        Acta Chir Scand. 1980; 146: 267-269
        • Juul K.
        • Tybjaerg-Hansen A.
        • Schnohr P.
        • Nordestgaard B.G.
        Factor V Leiden and the risk for venous thromboembolism in the adult Danish population.
        Ann Intern Med. 2004; 140: 330-3377
        • Oger E.
        • for the EPI-GETBO Study Group
        Incidence of venous thromboembolism: a community-based study in western France.
        Thromb Haemost. 2000; 83: 657-660
        • Gjores J.E.
        The incidence of venous thrombosis and its sequelae in certain districts of Sweden.
        Acta Chir Scand Suppl. 1956; 206: 1-88
        • Coon W.W.
        • Willis P.W.
        • Keller J.B.
        Venous thromboembolism and other venous disease in the Tecumseh community health study.
        Circulation. 1973; 48: 839-846
        • Royal College of General Practitioners
        Oral contraceptives and health: an interim report from the oral contraception study of the Royal College of General Practitioners.
        Pitman Medical, London1974
        • Kay C.R.
        Oral contraceptives and venous thrombosis (letter).
        Lancet. 1975; 1: 1381
        • Royal College of General Practitioners
        Oral contraception study. Oral contraceptives, venous thrombosis, and varicose veins.
        J R Coll Gen Pract. 1978; 28: 393-399
        • Vessey M.
        • Doll R.
        • Peto R.
        • Johnson B.
        • Wiggins P.
        A long-term follow-up study of women using different methods of contraception ��� an interim report.
        J Biosoc Sci. 1976; 8: 373-427
        • Vessey M.P.
        • Mann J.I.
        Female sex hormones and thrombosis.
        Br Med Bull. 1978; 34: 157-162
        • Vessey M.
        • Mant D.
        • Smith A.
        • Yeates D.
        Oral contraceptives and venous thromboembolism: findings in a large prospective study.
        BMJ. 1986; 292: 526
        • Heinemann L.A.J.
        • DoMinh T.
        • Assmann A.
        • et al.
        VTE risk assessment ��� a prognostic model: BATER cohort study of young women.
        Thrombosis J. 2005; 3 (18 April 2005) online: [Accessed Nov. 2, 2006].: 5
        • Dinger J.C.
        • Heinemann L.A.J.
        • Kuehl-Habich D.
        The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives (EURAS-OC) based on 142,475 women-years of observation.
        Contraception. 2007; 75: 344-354
        • Ludwig H.
        Anovulatory agents and venous disease.
        Ergebnisse Angiol Phlebolo. 1970; 4: 81-102
        • Fuertes de la Haba A.
        • Curet J.O.
        • Pelegrina I.
        • Bangdiwala I.
        Thrombophlebitis among oral and nonoral contraceptive users.
        Obstet Gynecol. 1971; 38: 259-263
        • Ridker P.M.
        • Glynn R.J.
        • Miletich J.P.
        • Goldhaber S.Z.
        • Stampfer M.J.
        • Hennekens C.H.
        Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.
        Ann Intern Med. 1997; 126: 528-531
        • Middeldorp S.
        • Meinardi J.R.
        • Koopman M.M.W.
        • et al.
        A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.
        Ann Intern Med. 2001; 135: 322-327
        • Writing Group for the Women's Health Initiative Investigators
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial.
        JAMA. 2002; 288: 321-333
        • The Women's Health Initiative Steering Committee
        Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial.
        JAMA. 2004; 291: 1701-1712
        • Porter J.B.
        • Hunter J.R.
        • Danielson D.A.
        • Jick H.
        • Stergachis A.
        Oral contraceptives and nonfatal vascular disease ��� recent experience.
        Obstet Gynecol. 1982; 59: 299-302
        • Gillum R.F.
        Pulmonary embolism and thrombophlebitis in the United States, 1970���1985.
        Am Heart J. 1987; 114: 1262-1264
        • Farmer R.D.T.
        • Preston T.D.
        The risk of venous thromboembolism associated with low oestrogen oral contraceptives.
        J Obstet Gynaecol. 1995; 15: 195-200
        • White R.H.
        • Zhou H.
        • Romano P.S.
        Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California.
        Ann Intern Med. 1998; 128: 737-740
        • Jick H.
        • Jick S.S.
        • Gurewich V.
        • Myers M.W.
        • Vasilakis C.
        Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
        Lancet. 1995; 346: 1589-1593
        • Gerstman B.B.
        • Piper J.M.
        • Freiman J.P.
        • et al.
        Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism.
        Int J Epidemiol. 1990; 19: 931-936
        • Farmer R.D.
        • Lawrenson R.A.
        • Thompson C.R.
        • Kennedy J.G.
        • Hambleton I.R.
        Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
        Lancet. 1997; 349: 83-88
        • Farmer R.D.
        • Lawrenson R.A.
        • Todd J.C.
        • Williams T.J.
        • MacRae K.
        Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK MediPlus Database.
        Hum Reprod. 1999; 5: 688-706
        • Jick H.
        • Kaye J.A.
        • Vasilakis-Scaramozza C.
        • Jick S.S.
        Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.
        BMJ. 2000; 321: 1190-1195
        • Drill V.A.
        Oral contraceptives and thromboembolic disease. I. Prospective and retrospective studies.
        JAMA. 1972; 219: 583-592